Fatty acid composition of the anterior cingulate cortex indicates a high susceptibility to lipid peroxidation in Parkinson's disease

Journal of Parkinson's Disease

Volumn 5, Issue 1, 2015, Pages 175-185

  Abbott, Sarah K ^a   Jenner, Andrew M ^a   Spiro, Adena S ^a   Batterham, Marijka ^a   Halliday, Glenda M ^b   Garner, Brett ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

F2 isoprostanes; fatty acids; lipid peroxidation; oxidative stress; Parkinson's disease; postmortem tissue analysis

Indexed keywords

ALPHA SYNUCLEIN; FATTY ACID; ISOPROSTANE DERIVATIVE; LIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID;

AGED; ANTERIOR CINGULATE; ARTICLE; AUTOPSY; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FATTY ACID ANALYSIS; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIPID COMPOSITION; LIPID PEROXIDATION; NEUROPATHOLOGY; OCCIPITAL CORTEX; OXIDATIVE STRESS; PARKINSON DISEASE; CINGULATE GYRUS; FEMALE; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FATTY ACIDS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GYRUS CINGULI; HUMANS; LIPID PEROXIDATION; MALE; PARKINSON DISEASE;

EID: 84923178540     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-140479     Document Type: Article

References (65)

1. Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci, 991, 1-14.
2. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, & Halliday G (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med, 16, 653-661.
3. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy. J, Leverenz JB, Del Tredici K, Wszolek ZK, Litvan I (2009) Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurol 8, 1150-1157.
4. Gai WP, Yuan HX, Li XQ, Power JT, Blumbergs PC, & Jensen PH (2000) In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol, 166, 324-333.
5. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, &Double KL (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain, 128, 2654-2664.
6. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211.
7. Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, & Ahlskog JE (2009) Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord, 15(Suppl 3), S1-S5.
8. Halliday GM, & McCann H (2010) The progression of pathology in Parkinson's disease. Ann N Y Acad Sci, 1184, 188-195.
9. Fahn S, & Cohen G (1992) The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann Neurol, 32, 804-812.
10. Selley ML (1998) (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med, 25, 169-174.
11. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol, 53 Suppl 3, S26-36; discussion S36-28.
12. Danielson SR, & Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med, 44, 1787-1794.
13. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ, 2nd, Morrow JD, & Montine TJ (2004) Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids, 128, 117-124.
14. Ruiperez V, Darios F, & Davletov B (2010) Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res, 49, 420-428.
15. Farooqui T, & Farooqui AA (2011) Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Parkinsons Di, 2011, 247467.
16. Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, & Becker G (2001) Brain iron pathways and their relevance to Parkinson's disease. J Neurochem, 79, 225-236.
17. Double KL, Gerlach M, Schunemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, & Ben-Shachar D (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol, 66, 489-494.
18. Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, &Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem, 75, 2583-2589.
19. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord, 13(Suppl 1), 24-34.
20. Garcia-Garcia A, Zavala-Flores L, Rodriguez-Rocha H, &Franco R (2012) Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease. Antiox Redox Signal, 17, 1764-1784.
21. Sutachan JJ, Casas Z, Albarracin SL, Stab BR, 2nd, Samudio I, Gonzalez J, Morales L, & Barreto GE (2012) Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr Neurosci, 15, 120-126.
22. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, & Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 114, 1953-1975.
23. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, & Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem, 52, 381-389.
24. Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, & Shankar SK (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: Implications for Parkinson's disease. Neurochem Res, 37, 358-369.
25. Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, Srinivas Bharath MM, & Shankar SK (2011) Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem Res, 36, 1452-1463.
26. Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, &Allsop D (2001) alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med, 30, 1163-1170.
27. Giasson BI, Ischiropoulos H, Lee VM, & Trojanowski JQ (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med, 32, 1264-1275.
28. Sharon R, Bar-Joseph I, Mirick GE, Serhan CN, & Selkoe DJ (2003) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J Biol Chem, 278, 49874-49881.
29. Zhu M, Qin ZJ, Hu D, Munishkina LA, & Fink AL (2006) Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry (Mosc), 45, 8135-8142.
30. Leong SL, Pham CL, Galatis D, Fodero-Tavoletti MT, Perez K, Hill AF, Masters CL, Ali FE, Barnham KJ, & Cappai R (2009) Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med, 46, 1328-1337.
31. Holman RT (1954) Autoxidation of fats and related substances. Prog Chem Fats other Lipids, 2, 51-98.
32. Cosgrove JP, Church DF, & Pryor WA (1987) The kinetics of the autoxidation of polyunsaturated fatty acids. Lipids, 22, 299-304.
33. Hulbert AJ (2005) On the importance of fatty acid composition of membranes for aging. J Theor Biol, 234, 277-288.
34. Hulbert AJ, Kelly MA, & Abbott SK (2014) Polyunsaturated fats, membrane lipids and animal longevity. J Comp Physiol B, 184, 149-166.
35. Bousquet M, Calon F,&Cicchetti F (2011) Impact of omega-3 fatty acids in Parkinson's disease. Ageing Res Rev, 10, 453-463.
36. Abbott SK, Li H, Sanz Muñoz S, Knoch B, Batterham M, Murphy KE, Halliday GM, & Garner B (2014) Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease. Mov Disord, 29, 518-526.
37. Bhatia S, Jenner AM, Li H, Ruberu K, Spiro AS, Shepherd CE, Kril JJ, Kain N, Don A, & Garner B (2013) Increased apolipoprotein D dimer formation in Alzheimer's disease hippocampus is associated with lipid conjugated diene levels. J Alzheimers Dis, 35, 475-486.
38. Halliday G, Ng T, Rodriguez M, Harding A, Blumbergs P, Evans W, Fabian V, Fryer J, Gonzales M, Harper C, Kalnins R, Masters CL, McLean C, Milder DG, Pamphlett R, Scott G, Tannenberg A, & Kril J (2002) Consensus neuropathological diagnosis of common dementia syndromes: Testing and standardising the use of multiple diagnostic criteria. Acta Neuropathol, 104, 72-78.
39. Murphy KE, Cottle L, Gysbers AM, Cooper AA, & Halliday GM (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commu, 1, 11.
40. Abbott SK, Jenner AM, Mitchell TW, Brown SH, Halliday GM, & Garner B (2013) An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids, 48, 307-318.
41. Abbott SK, Else PL, Atkins TA, & Hulbert AJ (2012) Fatty acid composition of membrane bilayers: Importance of diet polyunsaturated fat balance. Biochim Biophys Acta, 1818, 1309-1317.
42. Benjamini Y, & Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B, 57, 289-300.
43. Team RDC (2008) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria., ISBN 3-900051-900007-900050, URL http://www.R-project.org
44. Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, & Beach TG (2012) Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol, 22, 745-756.
45. Zhou J, Broe M, Huang Y, Anderson JP, Gai WP, Milward EA, Porritt M, Howells D, Hughes AJ, Wang X, & Halliday GM (2011) Changes in the solubility and phosphorylation of alpha-synuclein over the course of Parkinson's disease. Acta Neuropathol, 121, 695-704.
46. Sayre LM, Smith MA, & Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem, 8, 721-738.
47. Huttner WB, & Schmidt A (2000) Lipids, lipid modification and lipid-protein interaction in membrane budding and fission-insights from the roles of endophilin A1 and synaptophysin in synaptic vesicle endocytosis. Curr Opin Neurobiol, 10, 543-551.
48. Sanchez-Mejia RO, & Mucke L (2010) Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta, 1801, 784-790.
49. de Lau LM, Bornebroek M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM (2005) Dietary fatty acids and the risk of Parkinson disease: The Rotterdam study. Neurology 64, 2040-2045.
50. Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, & Nagai M (2010) Dietary fat intake and risk of Parkinson's disease: A case-control study in Japan. J Neurol Sci, 288, 117-122.
51. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, & Halliday GM (2014) Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain, 137, 834-848.
52. Julien C, Berthiaume L, Hadj-Tahar A, Rajput AH, Bedard PJ, Di Paolo T, Julien P, & Calon F (2006) Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int, 48, 404-414.
53. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, & Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A, 100, 5473-5478.
54. Seet RC, Lee CY, Lim EC,Tan JJ, Quek AM, Chong WL, Looi WF, Huang SH, Wang H, Chan YH, & Halliwell B (2010) Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med, 48, 560-566.
55. Fessel JP, Hulette C, Powell S, Roberts LJ, 2nd, & Zhang J (2003) Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem, 85, 645-650.
56. Pratico D, Lee VM-Y, Trojanowski JQ, Rokach J, & Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J, 12, 1777-1783.
57. Perrin RJ, Woods WS, Clayton DF, & George JM (2001) Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem, 276, 41958-41962.
58. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, & Selkoe DJ (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron, 37, 583-595.
59. Markesbery WR, & Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging, 19, 33-36.
60. Browne SE, Ferrante RJ, & Beal MF (1999) Oxidative stress in Huntington's disease. Brain Pathol, 9, 147-163.
61. Pedersen WA, Fu W, Keller JN, Markesbery WR, Appel S, Smith RG, Kasarskis E, & Mattson MP (1998) Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol, 44, 819-824.
62. Reed TT (2011) Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 51, 1302-1319.
63. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med, 23, 134-147.
64. Fraser T, Tayler H, & Love S (2010) Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res, 35, 503-513.
65. Lam SM, Wang Y, Duan X, Wenk MR, Kalaria RN, Chen CP, Lai MK, & Shui G (2014) The brain lipidomes of subcortical ischemic vascular dementia and mixed dementia. Neurobiol Aging, 35, 2369-2381.